25.11.2024 – 13:52Helmholtz Zentrum MünchenInceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapiesmehr
14.11.2024 – 14:00ARTTIC Innovation GmbHLast Call for canSERV Third Open Call FundingOpen CallEin Dokumentmehr
17.09.2024 – 14:05ARTTIC Innovation GmbHLaunch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"Challenge CallEin Dokumentmehr
04.09.2024 – 15:13Fördergesellschaft IZB mbH2Record financing rounds at the Munich biotech hubFind out more about the 40+ biotech start-ups at the IZBEin Dokumentmehr
29.08.2024 – 14:03ARTTIC Innovation GmbHcanSERV relaunches Open Call for Service ProvisionOpen CallEin Dokumentmehr
02.07.2024 – 14:00ARTTIC Innovation GmbHcanSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision OpencanSERV Challenge Calls2 Dokumentemehr
28.05.2024 – 14:05ARTTIC Innovation GmbHcanSERV invites applications for "Revolutionising Cancer Patient Care"canSERV Challenge CallEin Dokumentmehr
28.05.2024 – 14:00ARTTIC Innovation GmbH3canSERV invites applications for "Revolutionising Cancer Patient Care"canSERV CallEin Dokumentmehr
21.05.2024 – 08:13Helmholtz Zentrum MünchenNew Study: Night-time heat significantly increases the risk of strokeNewsroommehr
14.05.2024 – 09:01ARTTIC Innovation GmbHLAST CHANCE: canSERV Second Open Call for Cancer Research Service ProvisioncanSERV Open Call Ein Dokumentmehr
23.04.2024 – 14:02ARTTIC Innovation GmbH3canSERV Initiative: EU Consortium Launches Groundbreaking Call to Accelerate Cancer ResearchcanSERV Challenge CallEin Dokumentmehr
02.04.2024 – 11:10Helmholtz Zentrum MünchenScientists Reveal Adipocyte's Metabolic Role and Identify Treatment Targetsmehr
28.02.2024 – 11:07Helmholtz Zentrum MünchenRising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Targetmehr
22.02.2024 – 14:10ARTTIC Innovation GmbHiMEDCAP: EU-Projekt leistet Pionierarbeit bei der Rettung verwundeter SoldateniMEDCAP Factsheet mehr
22.02.2024 – 13:23Helmholtz Zentrum MünchenTherapeutic Vaccine for Chronic Hepatitis B Enters Clinical TrialMore information on the therapeutic vaccine TherVacBmehr
19.02.2024 – 17:05Helmholtz Zentrum MünchenWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and ComplicationsLearn more about research at Helmholtz Munichmehr
18.01.2024 – 10:00ARTTIC Innovation GmbH2OPTIMA cancer project announces the Region Uppsala as new partnerCheck out the OPTIMA Videomehr
08.12.2023 – 11:13Helmholtz Zentrum MünchenNew Source of Stem Cells in Injury-Affected Brains of Patientsmehr
23.11.2023 – 20:15Fraunhofer-Institut für Produktionstechnologie IPTPooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systemsPress release and imagesmehr
31.10.2023 – 10:00ARTTIC Innovation GmbH2PIONEER+ becomes Big Data Platform for Prostate Cancer of the EAU's UroEvidenceHubPIONEER Videomehr
12.10.2023 – 14:01ARTTIC Innovation GmbH3EU Provides 1 Mio. to Researchers to Advance Personalised OncologycanSERV CallEin Dokumentmehr
12.10.2023 – 14:00ARTTIC Innovation GmbHcanSERV Releases Open Call for Transnational Service ProvisioncanSERV CallEin Dokumentmehr
09.08.2023 – 16:52Helmholtz Zentrum MünchenA New Ally in Fighting Brain Diseases: Our Very Own Skullmehr
08.08.2023 – 08:00ARTTIC Innovation GmbH4PIONEER Big Data in Prostate Cancer Platform Opens up to Asian Data SetsMore about PIONEERmehr
07.08.2023 – 11:31Helmholtz Zentrum MünchenLife Science Factory to Open a New Location in Munich in 2024mehr
30.06.2023 – 10:09ARTTIC Innovation GmbH2CARAMBA: New Hope for Multiple Myeloma PatientsCARAMBA project websitemehr
15.06.2023 – 09:36Berlin CuresBerlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth / Phase II study for BC 007 in the indication Long COVID to start in Junemehr
27.02.2023 – 13:20Helmholtz Zentrum MünchenType 1 Diabetes Awareness Campaign - K1DS ARE HEROES - startedmehr
09.11.2022 – 10:39RHEACELL GmbH und Co. KGStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa researchmehr